
In PV industry, most of the operations, e.g., detecting and reporting ADRs, assessment of its seriousness and causal relationship with the suspected drug, coding of adverse events in technical terms, preparing safety reports of individual cases, depending upon the human interventions which consume a lot of time.
For such situation, an effort by regulatory authorities is the discussion related to the machine learning (ML) technology which could support PV because this technology requires no translator to translate the codes of ADRs used under PV system and it can learn by its own without human intervention.
In drug development, it can enhance the stages of the drug discovery process (chemical structure of the drug, identification of the effect of the drug in both preclinical and clinical trials, etc.)
by analyzing and interpreting the biomedical data from research experiments to predict the ADRs of the drug.
The AI-led PV system can automatically extract and code ADR data from multiple sources to reduce case processing effort.
By adopting such a knowledge-driven idea, there is an evident rise in the journals, media, and articles that some pharmaceutical companies tie-up with IT companies and launch AI-based solutions for drug safety.